Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous tumor killer cells

A preparation of autologous tumor killer cells (TKCs) which consists of the innate immune cells natural killer (NK) cells and gamma delta T (gdT) cells, which are T lymphocytes that express only gamma chain and delta chain T-cell receptors (TCRs), with potential cytolytic and antineoplastic activities. NK cells and gdT cells are isolated from the patients' peripheral blood mononuclear cells (PBMCs) and co-cultured ex vivo in a certain proportion with TKC technology. Upon administration, autologous TKCs may lyse cancer cells, and further stimulate an anti-tumor immune response.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous NK cells/gamma-delta-T cells
autologous NK/gd-T cells
autologous TKCs
co-cultured autologous NK cells and gdT cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search